Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zimberelimab with Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer
NCT05437692Phase 2Unknown
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jul 2022
- Primary completion
- Jul 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of zimberelimab in Cervical Cancer (CC), sponsored by Zhongshan Hospital, Fudan University. Status: unknown.
02
Drugs
zimberelimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT05437692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05437692.